NRx Pharmaceuticals, Inc. (NRXP) Reports Q2 Loss, Misses Revenue Estimates
NRx Pharmaceuticals, Inc. (NRXP) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.98 per share a year ago.
NRx Pharmaceuticals Nears FDA Decision on Preservative-Free Ketamine After Review Clears Hurdles
NRx Pharmaceuticals NASDAQ: NRXP said it has completed the first-cycle U.S. Food and Drug Administration review of its abbreviated new drug application, or ANDA, for preservative-free ketamine, with one remaining issue related to the product's vial connector.
NRx Pharmaceuticals Q1 Earnings Call Highlights
NRx Pharmaceuticals NASDAQ: NRXP said it advanced several regulatory, manufacturing and clinical initiatives during the first quarter of 2026, including progress toward potential approval of its preservative-free ketamine product, KETAFREE, and preparations for an NDA filing for NRX-100.
NRx Pharmaceuticals, Inc. (NRXP) Reports Q1 Loss, Lags Revenue Estimates
NRx Pharmaceuticals, Inc. (NRXP) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.34 per share a year ago.
NRx Pharmaceuticals, Inc. (NRXP) Q4 2025 Earnings Call Transcript
NRx Pharmaceuticals, Inc. (NRXP) Q4 2025 Earnings Call Transcript
NRx Pharmaceuticals, Inc. (NRXP) Surpasses Q4 Earnings Estimates
NRx Pharmaceuticals, Inc. (NRXP) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of a loss of $0.09 per share. This compares to a loss of $0.3 per share a year ago.
NRx Pharmaceuticals, Inc. (NRXP) Shareholder/Analyst Call Prepared Remarks Transcript
NRx Pharmaceuticals, Inc. (NRXP) Shareholder/Analyst Call Prepared Remarks Transcript
NRx Pharmaceuticals, Inc. (NRXP) Discusses Regulatory Update and Development Pipeline Expansion for Preservative-Free Ketamine Formulation Transcript
NRx Pharmaceuticals, Inc. (NRXP) Discusses Regulatory Update and Development Pipeline Expansion for Preservative-Free Ketamine Formulation Transcript
NRx Pharmaceuticals, Inc. (NRXP) Q3 2025 Earnings Call Transcript
NRx Pharmaceuticals, Inc. ( NRXP ) Q3 2025 Earnings Call November 17, 2025 8:30 AM EST Company Participants Matthew Duffy - Chief Business Officer & Co-CEO of Hope Therapeutics Michael Abrams - Chief Financial Officer Jonathan Javitt - Co-Founder, Chief Scientist Officer, Chairman & Interim CEO Conference Call Participants Thomas Shrader - BTIG, LLC, Research Division Patrick Trucchio - H.C. Wainwright & Co, LLC, Research Division Edward Woo - Ascendiant Capital Markets LLC, Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to the NRx Pharmaceuticals' Q3 2025 Earnings Conference Call.
NRx Pharmaceuticals, Inc. (NRXP) Q2 2025 Earnings Call Transcript
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q2 2025 Earnings Conference Call August 20, 2025 8:00 AM ET Company Participants Jonathan C. Javitt - Co-Founder, Chief Scientist Officer, Chairman & Interim CEO Matthew Patrick Duffy - Chief Business Officer & Co-CEO of Hope Therapeutics Michael S.
NRx Pharmaceuticals, Inc. (NRXP) Q1 2025 Earnings Call Transcript
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET Company Participants Matthew Duffy – Chief Business Officer Jonathan Javitt – Founder, Chairman, and Chief Executive Officer Michael Abrams – Chief Financial Officer Conference Call Participants Tom Shrader – BTIG Ed Woo – Ascendiant Capital Operator Good afternoon, ladies and gentlemen, and welcome to the NRx Pharmaceuticals First Quarter 2025 Earnings Call. At this time, all lines are in a listen-only mode.
Here's Why NRx Pharmaceuticals (NRXP) Is a Great 'Buy the Bottom' Stock Now
NRx Pharmaceuticals (NRXP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
